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Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary
haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced
non-squamous non-small-cell lung cancer (NSCLC).
Methods: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify
predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC.
Results: Patients with NSCLC are at an increased risk of PH owing to the underlying disease process. Patients with
squamous histology and/or a history of grade ‡2 haemoptysis (‡2.5 ml per event) should not receive bevacizumab. No
clinical or radiological features (including cavitation and central tumour location) reliably predict severe PH in
bevacizumab-treated patients. Major blood vessel inﬁltration and bronchial vessel inﬁltration, encasement and abutting
may predict PH; however, standardised radiological criteria for deﬁning inﬁltration have not been established. Eligibility
for bevacizumab is not affected by patient age, performance status or anticoagulation or antiplatelet therapy.
Conclusions: An individualised risk–beneﬁt assessment should be undertaken in all patients with NSCLC in whom
bevacizumab is being considered. Further research is required to elucidate the mechanisms underlying PH and the
clinical risk factors.
Key words: bevacizumab, carcinoma, haemorrhage, haemoptysis, non-small-cell lung cancer, safety
introduction
Bevacizumab is a recombinant, humanised monoclonal
antibody against vascular endothelial growth factor (VEGF)
[1]. Bevacizumab is currently the only anti-angiogenesis agent
approved for the treatment of lung cancer [1, 2]. In randomised
phase II and III clinical trials, bevacizumab prolonged overall
survival [3, 4] and progression-free survival [3–7] when added
to standard platinum-based chemotherapy regimens for the
ﬁrst-line treatment of patients with recurrent or advanced
(stage IIIB or IV) non-squamous NSCLC. European guidelines
recommend that bevacizumab is included within the ﬁrst-line
treatment of selected patients with stage IV non-squamous
NSCLC [8]. The USA National Cancer Institute also advises
that certain patients with non-squamous NSCLC may beneﬁt
from bevacizumab [9]. Other anti-angiogenesis drugs are under
evaluation for the treatment of NSCLC, but their value has yet
to be established [10, 11].
The tolerability proﬁle of bevacizumab in patients with
NSCLC has been documented in phase III/IV trials and the
Avastin Regimens: Investigation of treatment Effects and Safety
(ARIES) observational cohort study [3, 5, 12–14; Dansin E,
Cinieri S, Garrido P et al. (unpublished data)]. Concerns exist
regarding the small increased risk of clinically signiﬁcant (grade
‡3) or fatal (grade 5) pulmonary haemorrhage (PH) in patients
treated with bevacizumab and other anti-VEGF agents. Two
meta-analyses have found that the use of bevacizumab
in combination with chemotherapy for the treatment of
various tumour types conferred a signiﬁcantly increased risk
of severe and fatal bleeding events [15] and treatment-related
mortality [16] versus chemotherapy alone. However, these
meta-analyses pooled phase II and III studies of ﬁrst- and
second-line therapy and did not take account of the evolution
in patient selection criteria that has been associated with
a reduction in the risk of PH during ﬁrst-line bevacizumab
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PH is distressing and potentially life threatening [17, 18].
Concerns and misunderstandings regarding the risk of severe
PH during bevacizumab therapy for non-squamous NSCLC,
and on the risk : beneﬁt ratio of treatment, may cause
clinicians to inappropriately avoid the use of the drug in
patients who might beneﬁt from it. Accordingly, a panel of
expert oncologists, pulmonologists and radiologists reviewed
the available data to identify predictive factors for PH in order
to help guide physicians using bevacizumab in this setting.
PH in patients with NSCLC
Lung cancer accounts for 20% to 30% of cases of PH, as
manifested by haemoptysis [19–21]. Haemoptysis is among the
most frequent presenting symptoms of lung cancer, being
reported in 30% to 60% of patients in case series [22, 23].
However, while patients with NSCLC at increased risk of PH,
there are few robust data on its incidence in untreated patients.
According to one retrospective case series, non-life-threatening
PH occurred in 16.0% of 877 patients with lung cancer and was
fatal in 3.3% [17]. Massive PH was signiﬁcantly associated with
squamous cell tumours, cavitation and with bronchial (versus
peripheral) tumours [17]. Other estimates suggest that up to
90% of PH events occur from the bronchial artery [24].
The pathophysiology of PH in patients with NSCLC is poorly
understood. Suggested mechanisms include neovascularisation,
exposure of blood vessels by exfoliation of surface tumour cells,
tumour necrosis, trauma from cough and invasive procedures
(e.g. bronchoscopy) and the formation of airway-vascular
ﬁstulae [25].
PH in bevacizumab-treated patients
incidence and severity
Life-threatening PH occurred in 6 of 67 (90%) patients with
NSCLC treated with bevacizumab during a phase II trial
(AVF0757g); four events were fatal [26]. All six patients had
‘centrally located tumours close to major blood vessels’; ﬁve
had cavitation or tumour necrosis and four had squamous
cell carcinomas. There was only a small increased risk of
grade ‡3 bleeding (4%) in patients with non-squamous
tumours [26].
Phase III studies of bevacizumab in patients with
NSCLC—the Eastern Cooperative Oncology Group (ECOG)
4599 and the Avastin in Lung study (AVAiL)—excluded
patients with predominantly squamous cell tumours (i.e. >50%
of squamous cells in the sample used for histological diagnosis
by a pathologist) and those with signiﬁcant PH (i.e.
haemoptysis of ‡2.5 ml per event). Criteria concerning
haemorrhagic diseases and anticoagulation therapy were also
employed [3, 5]. AVAiL also excluded patients with tumours
invading or abutting major blood vessels, based on a local
radiological assessment [5]. In ECOG 4599, grade ‡3 PH was
reported in eight (1.9%) bevacizumab recipients and was fatal
in ﬁve (1.2%) (Table 1). One grade 3 event (0.2%) occurred in
the chemotherapy group [3]. In AVAiL, grade ‡3 PH was
reported in ﬁve patients (1.5%) treated with bevacizumab
7.5 mg/kg, three (0.9%) treated with 15.0 mg/kg and two (0.6%)
who received chemotherapy alone. The incidences of fatal PH
in these groups were 1.2%, 0.9% and 0.3%, respectively [5].
According to the Safety of Avastin in Lung cancer (SAiL)
study (MO19390) [12] and the observational ARIES registry
[13, 14], rates of severe PH in clinical practice are low and
similar to those in phase III trials. SAiL was a single-arm phase
IV study performed in 400 centres in 40 countries [12]. Like
AVAiL, SAiL excluded patients with a history of signiﬁcant PH
(haemoptysis of ‡2.5 ml per event) and radiological evidence of
a tumour invading or abutting major blood vessels. However,
a broader patient range was recruited, e.g. in terms of age,
chemotherapy regimens, performance status and
anticoagulation. At baseline in SAiL, 578 (26.1%) of 2212
patients treated had a centrally located tumour and 56 (2.5%)
had cavitation. Overall, grade ‡3 bleeding events occurred in 80
patients (3.6%) and were fatal in 17 patients (0.8%). Bleeding
caused the temporary interruption of bevacizumab treatment
in 28 of 1347 events (2.0%) and its permanent cessation in 110
events (8.2%). Grade ‡3 PH occurred in 15 patients (0.7%),
a rate considered by the authors to be in the normal
background range. Eight patients (0.4%) died from PH events
[12]. The ARIES cohort also represents a broader population
than that treated in clinical trials. According to preliminary
data from 1489 patients treated in ARIES, 131 (8.8%) had an
ECOG performance status of two or more, 107 (7.2%) had
a history of haemoptysis and 282 patients (18.9%) were aged
‡75 years. To date, severe PH has occurred in 13 patients
(0.9%) and was fatal in four cases (0.3%) [14].
risk factors
The mechanisms by which anti-VEGF agents induce bleeding
are not well understood. It may result from the inhibition of
the physiological endothelial repair processes mediated by
VEGF [27]. Pathological changes due to cancer, e.g. tumour
erosion of vessels, may also be important [28]. Phase II data
suggested that centrally located tumours close to major blood
vessels might be linked to severe PH during bevacizumab
therapy. However, this was based on only six cases and these
tumour characteristics were not deﬁned according to
standardised radiological criteria [26]. Indeed, the validation
of any relationship between PH and tumour centrality or
vessel invasion, and the application of exclusion criteria for
patient selection, is hampered by the lack of precise,
standardised and well-accepted radiological deﬁnitions of
tumour centrality or vessel invasion. Furthermore, any
distinction between tumour centrality and vessel invasion is
complicated by their interrelationship, one being a risk factor
for the other.
Thoracic computed tomography (CT) is the principal tool in
evaluating NSCLC and eligibility for bevacizumab [29–31].
However, CT has limited accuracy in differentiating
mediastinal invasion from anatomic contiguity in lung cancer
[32–36]( Figures 1 and 2). Similar problems have been reported
during the development of CT-based grading systems for the
prediction of haemorrhage risk in patients with pancreatic
cancer [37, 38]. Multidetector CT may have advantages in this
regard, but the clinical impact of this technology has not been
assessed.
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1112 | Reck et al. Volume 23|No. 5|May 2012Table 1. Bleeding event rates in studies of bevacizumab in the treatment of advanced non-small-cell lung cancer
Event type Grade Phase II Phase III Phase IV
AVF0757g [26] ECOG 4599 [3, 40] AVAiL [5, 7]
SAiL [12, Dansin E,
Cinieri S, Garrido P et al.
(unpublished data)] ARIES [14]
B 7.5 mg/kg
+ CP
(n = 32)
B 15 mg/kg
+ CP
(n = 35)
CP
(n = 32)
B 15 mg/kg
+ CP
(n = 427)
CP
(n = 440)
B 7.5 mg/kg
+ CG
(n = 330)
B 15 mg/kg
+ CG
(n = 329)
CG
(n = 327)
B 7.5 or 15 mg/kg
+ chemo
a (n = 2212)
B + chemo
a
(n = 1489)
All bleeding
events, n (%)
‡3 5 (156) 1 (29) 0 19 (4.4)* 3 (0.7) 14 (4.2) 14 (4.3) 6 (1.8) 80 (3.6) 50 (3.4)
PH, n (%) ‡35
b (156) 1 (29) 0 8 (1.9) 1 (0.2) 5 (1.5) 3 (0.9) 2 (0.6) 15 (0.7) 13 (0.9)
54 ( 6 0) 0 5 (1.2) 0 4 (1.2) 3 (0.9) 1 (0.3) 8 (0.4) 4 (0.3)
Central tumour
Deﬁnition — Not deﬁned Within 2 cm of bronchus
and main and lobar
bronchi
Not deﬁned Not deﬁned <2.0 cm between
central-most
tumour edge
and trachea, main
bronchi and
lobular bronchi
Grade ‡3 PH incidence according to central location, n/N (%)
Central ‡35
b/ND (ND)
c 1/ND (ND)
c 0 3/ND (ND)
d ND 4/ND (ND)
e 4/578 (0.7) 9/731 (1.2)
Non-central ‡3 0 0 0 3/ND (ND)
d ND 6/ND (ND)
e 11/1633 (0.7) 4/758 (0.5)
Cavitation
Grade ‡3 PH incidence according to cavitation, n/N (%)
Cavitation ‡3 5/ND (ND)
f 2/ND (ND)
d ND ND ND ND 0/56 (0) 3/127 (1.4)
No cavitation ‡3 0 0 4/ND (ND)
d ND ND ND ND 15/2155 (0.7) 10/1272 (0.8)
aChosen at discretion of investigator/physician.
bIncludes two cases described as haematemesis.
cAll patients with grade ‡3 PH events had central tumour location. Publication provides no data on the total number of patients with and without central tumours.
dData from retrospective analysis [40]. Publication provides no data on the total number of patients with/without central tumours and with/without cavitation.
eAcross all study arms, 4/10 (40%) of grade ‡3 events occurred in patients with central tumours. No data on the total number of patients with and without central tumours are given.
fFive of six patients with grade ‡3 events had cavitation or necrosis of tumours, either at baseline or developing during bevacizumab therapy, but data according to dose group and overall rates of cavitation are
not published.
*P < 0.001 versus chemotherapy group.
ARIES, Avastin Regimens: Investigation of treatment Effects and Safety; AVAiL. Avastin in Lung; B, bevacizumab; CG, cisplatin plus gemcitabine; CP, carboplatin plus paclitaxel; ECOG, Eastern Cooperative
Oncology Group; ND, no data; PH, pulmonary haemorrhage; SAiL, Safety of Avastin in Lung.
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3The development of standard radiological criteria for tumour
centrality and vessel inﬁltration is crucial. It is also important to
recognise that variations between assessments may occur even
when criteria are standardised. Barlesi et al. [39]d e m o n s t r a t e d
discordance among radiologists and oncologists regarding
decisions on the eligibility of patients with NSCLC for
bevacizumab therapy based on proposed radiological criteria. In
this retrospective multicentre study, radiologists and oncologists
assessed proposed eligibility for bevacizumab based on 150 chest
CT scans from patients withc e n t r a lN S C L Ct u m o u r s .
Discordance in eligibility decisions occurred in 55% of the scans,
with signiﬁcant differences among physicians independent of
speciality (P < 0.05). Intraobserver variations between assessments
were greater for oncologists than radiologists. On multivariate
analysis, the assessment of the contact between tumour and the
vessel was the only criterion signiﬁcantly related to the risk of
discrepancy between physicians [39].
The assessment of bronchial vessel inﬁltration by
bronchoscopy is difﬁcult because a direct inﬁltration of
bronchial vessels located below the surface of the bronchial
epithelium cannot be detected by conventional bronchoscopy.
New techniques, such as autoﬂuorescence bronchoscopy, might
enable the detection of relevant inﬁltration of bronchial vessels
in the future.
central tumour location and vessel invasion. Although phase II
data suggested that central tumour location may be a risk factor
for PH in bevacizumab-treated patients [26], subsequent data do
not support this conclusion. Sandler et al. [40] carried out
a retrospective case–control analysis of grade ‡3 PH events in
AVF757g [26] and ECOG 4599 [3]. Patients with PH potentially
due to other confounding causes in ECOG 4599 were excluded.
Patients with PH were compared with age- and sex-matched
bevacizumab-treated controls. The incidence of PH was assessed
according to potentially relevant baseline tumour characteristics,
i.e. central tumour location (deﬁned as within 2 cm of bronchus)
versus peripheral epicentre (within 2 cm of a pleural surface or
other location), presence and size of cavitation and longest
diameter of largest nodal or tumour mass. Bronchial
involvement was assessed according to six categories relating to
contact of the tumour with the margin of the tracheobronchial
tree, encasement narrowing, presence of a mass with or without
consolidation and localised intralumenal soft tissue density.
Cavitation was found to be signiﬁcantly associated with severe
PH, as discussed below. However, there was no signiﬁcant
association between PH and lesion location, size or vascular
involvement and severe PH, although ‘suspicion of
endobronchial involvement’ was a signiﬁcant risk factor [odds
ratio (OR) 12.8; P = 0.024] [40]. These authors concluded that
patients with non-squamous NSCLC should not be excluded
from receiving bevacizumab therapy based solely on central
tumour location. In AVAiL, 4/10 (40.0%) patients with severe
PH had tumours described as central, although tumour centrality
was not deﬁned prospectively in the protocol [5]. This
proportion was similar to the proportion of all patients with
central tumours (38%), further suggesting that central tumour
location did not increase the risk of PH.
In SAiL, 578 patients (26.1%) had a centrally located lung
tumour, although no standardised deﬁnition was used. The
Figure 1. Thoracic computed tomography images that show no clear
vessel invasion by non-small-cell lung tumours. (A) Central tumour
with inﬁltration of main carina and both main bronchi but no evident
inﬁltration of large central blood vessels; (B) Central tumour with direct
inﬁltration of the mediastinum but no clear inﬁltration of central blood
vessels; (C) Central tumour touching without sign of pulmonary artery
inﬁltration. The presence of an atelectasis makes the interpretation difﬁcult
and may necessitate multiplanar reconstructions to aid decision making.
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tumours and 8.6% in those with non-central tumours. The
groups with central and non-central tumours were also similar
with regard to the rate of grade ‡3 PH (0.7% and 0.7%,
respectively) [Dansin E, Cinieri S, Garrido P et al. (unpublished
data)] and the proportion of all PH events that were fatal (5.6%
and 3.2%, respectively) [41].
In ARIES, central tumours were deﬁned as those showing
a distance of <2.0 cm between central-most tumour edge and
the trachea, main bronchi and lobular bronchi. As of February
2010, 49% of patients (n = 1489) had at least one central
tumour at baseline [14]. The rate of grade ‡3 PH in patients
with centrally located tumours was 1.2% compared with 0.5%
in patients without centrally located tumours (Table 1).
Grade ‡3 PH was not signiﬁcantly associated with central
tumour location, the presence or size of cavitations or the size
or number of measurable tumours. Although the number of
cases is small, this cohort is larger, and hence potentially more
reliable, than the original phase II study that raised concerns
regarding central tumours and PH risk [26].
cavitation. Approximately 15% of patients may have
cavitations before the initiation of bevacizumab in clinical
practice [14]. Approximately 15%–24% of patients with
NSCLC develop pulmonary cavitation after treatment with
angiogenesis inhibitors (Figure 3)[ 42, 43]. This is thought to
be due to the central necrosis of lesions after inhibition of
angiogenesis and appears more likely to occur in squamous
cell tumours [43].
A retrospective analysis showed that cavitation was the only
signiﬁcant predictive factor for severe PH during bevacizumab
therapy [40]. In ECOG 4599, cavitation was present in 2 of 6
patients with severe PH compared with 1 of 29 matched
controls (P = 0.034). There was a nonsigniﬁcant association
between baseline cavitation and severe PH when phase II/III
data were pooled. Post-baseline cavitation was associated with
PH (P = 0.02).
In contrast, other data do not show a relationship between
cavitation and PH during anti-angiogenesis therapy. According
to a retrospective single-centre study, pre-existing cavitations
were present in 13% of 124 patients treated with anti-
angiogenesis agents in clinical trials and in 9% of those with non-
squamous tumours [43]. Overall, cavity formation occurred in
16% of patients with no pre-existing cavitations and was more
frequent in patients with squamous cell tumours (P = 0.04) and
current smokers (P = 0.02). Haemoptysis was associated with
Figure 2. Thoracic computed tomography images illustrating cases of clear vessel invasion by non-small-cell lung tumours. (A) Central tumour with clear
circulation and inﬁltration of central blood vessels; (B) Concave impression of tumour tissue into the lumen of the pulmonary vessel as sign of vessel
inﬁltration; (C) Diffuse inﬁltration of subclavian artery by tumour tissue; (D) Diffuse inﬁltration of left lower pulmonary artery by tumour tissue.
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cavitation, or with cavity size or cavity : mass ratio, histology or
central tumour location. Haemoptysis occurred more commonly
with tumours involving a segmental airway or artery rather than
a main bronchus or artery [43].
In SAiL, the rates of grade ‡3 PH were similar in patients
with (0.0%) and without cavitation (0.7%) [Dansin E,
Cinieri S, Garrido P et al. (unpublished data)] (Table 1).
Preliminary data from the ARIES cohort also suggest that
cavitation does not predict PH during bevacizumab therapy.
The rate of grade ‡3 PH in patients with cavitation in
measurable tumours was 1.4% compared with 0.8% in patients
without cavitation (Table 1). Analysis revealed no signiﬁcant
associations between the presence and size of cavitations [14].
A substudy of 198 patients showed that 25 (12.6%) had
cavitation at baseline and 59 (29.8%) developed new or
enlarged cavitations during bevacizumab therapy. Presence of
pre-existing cavitations, multiple measurable tumours and large
tumours were associated with the development of on-study
cavitations. Two patients developed severe PH during
bevacizumab therapy; neither event was fatal and neither patient
had new or enlarged cavitations post-baseline. No statistically
signiﬁcant association was found between the development of
on-treatment cavitation and severe PH incidence [44]. These
ﬁndings, although limited by the small number of events,
suggest that neither baseline cavitation nor the development of
cavitations alone is a risk factor for severe PH.
other factors. Phase II evidence suggesting that severe PH during
bevacizumab therapy was linked with squamous histology [26]l e d
to the exclusion of patients with predominantly squamous
tumours from subsequent trials. However, as squamous cell
tumours are more likely to be centrally located and to be cavitated
compared with adenocarcinoma, it is not clear whether this
histology is an independent risk factor or simply a surrogate
marker [26]. The Avastin in Squamous NSCLC (AVASQ) trial
(BO19734) evaluated the safety of bevacizumab added to
cisplatin–gemcitabine from cycle 2 onwards, as compared
with cisplatin–gemcitabine alone, in patients with advanced
squamous NSCLC [45]. Eligible patients were at risk of PH owing
to the presence of central tumours or peripheral tumours with
longest diameter ‡2 cm, which had not been irradiated previously.
Patients who had experienced grade ‡2h a e m o p t y s i su pt o3
months before study entry were not eligible. All patients received
a short course of radiation therapy 3 weeks before starting
chemotherapy. The study was terminated early after 2 of the ﬁrst
20 bevacizumab-treated patients (10.0%) experienced grade ‡3
PH [45]. The implications of these data for current patient
selection are unclear owing to the multiple potential PH risk
factors present in this population, including squamous histology.
The open-label, single-arm phase II BRIDGE study
investigated whether the risk of PH in patients with squamous
NSCLC could be reduced by delaying the initiation of
bevacizumab and selecting patients without baseline risk factors
for PH [45]. Exclusion criteria for BRIDGE included a history
of gross haemoptysis and cavitation at baseline. Patients
received carboplatin/paclitaxel for two cycles, followed by
carboplatin/paclitaxel and bevacizumab in cycles 3–6 and then
bevacizumab monotherapy. Grade ‡3 PH occurred in 1 of 31
patients, i.e. 3.2% [45]. Although this incidence was lower than
that in the AVF0757g study [26], the use of bevacizumab in
squamous NSCLC remains experimental.
The phase III trials of bevacizumab excluded patients with
a history of clinically signiﬁcant PH. More recently, the
observational ARIES study did not exclude patients with
a history of PH. According to preliminary data, grade ‡3P H
events were reported in 4 of 140 patients with a history of
haemoptysis at baseline [2.9%; 95% conﬁdence interval (CI)
0.8% to 7.2%], compared with 11 of 1814 patients (0.6%; 95%
CI 0.3% to 1.1%) without a history of haemoptysis [13].
A cohort analysis of phase II and ECOG 4599 data showed no
statistically signiﬁcant association between severe PH and
baseline sex, age, ECOG performance score, prior treatment
with radiation therapy or prior thoracic surgery [40]. The safety
of NSCLC treatments in the elderly is an important
consideration, as the mean age lung cancer diagnosis is 70 years
[46]. According to a retrospective analysis of ECOG 4599, 1 of
111 (0.9%) bevacizumab recipients aged >70 years experienced
grade 3 PH and 2 (1.8%) died from PH [47]. However, in
AVAiL, no elderly patients (aged ‡65 years) experienced PH, as
Figure 3. Thoracic computed tomography illustrating cavitation occurring during bevacizumab therapy. The patient was diagnosed with stage IV
cT4N2M1 pulmo-adenocarcinoma and was treated with bevacizumab (7.5 mg/kg) in combination with carboplatin and gemcitabine. (A) Image before
therapy; (B) Image after two cycles of bevacizumab plus chemotherapy; (C) After 10 cycles of bevacizumab maintenance therapy.
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patients treated with bevacizumab 7.5 mg/kg and 15.0 mg/kg,
respectively [48]. In SAiL, the incidence of all bleeding was
similar in patients aged >65 years (43.0% of 623 patients) and
£65 years (42.1% of 1589), as was the rate of grade ‡3P H
(0.6% vs 0.7%, respectively) [Dansin E, Cinieri S, Garrido P
et al. (unpublished data)]. Also, in ARIES there was no increase
in severe PH in elderly patients as compared with the overall
population [14]. Taken together, these data suggest that the risk
of PH during bevacizumab therapy is not increased in the
elderly as compared with younger patients.
The eligibility for bevacizumab is not affected by
anticoagulation [1]. Overall, 9% of patients in the AVAiL study
received therapeutic anticoagulation post-baseline and no PH
events were observed in these patients [5]. Pooled data from
three randomised phase III studies showed similar rates of
bleeding events with bevacizumab and placebo in patients with
NSCLC or metastatic colorectal cancer treated concurrently
with full-dose therapeutic anticoagulation [49]. In the SAiL
study, 83 patients (3.8%) were receiving anticoagulant therapy
at baseline, while 328 patients (14.8%) received anticoagulants
during the study. The incidence of bleeding events, including
grade ‡3 PH, was similar in patients receiving anticoagulants
versus those not receiving anticoagulation therapy [Dansin E,
Cinieri S, Garrido P et al. (unpublished data)]. The use of
bevacizumab is not affected by antiplatelet therapy and 23.3%
of patients in the ARIES cohort were using antiplatelet therapy
at the initiation of bevacizumab therapy [14].
practical management of PH in
bevacizumab-treated patients
There are few robust data on the management of PH in patients
with advanced lung cancer. The incidence of severe PH in patients
treated with anti-VEGF agents is low and to our knowledge, no
studies have speciﬁcally investigated its optimal treatment. As
there are no speciﬁc recommendations available for the treatment
of PH associated with bevacizumab therapy, guidelines for the
general management of PH are also used for this purpose.
Severe PH is a medical emergency requiring specialised
management and patients with massive bleeding are typically
cared for in the intensive care unit [50]. Bevacizumab should be
discontinued permanently in patients who experience grade 3
or 4 bleeding during therapy [1]. Supportive measures include
airway maintenance with endotracheal intubation, together
with cardiorespiratory monitoring, correction of hypoxia,
stabilisation of blood pressure and blood transfusion as
necessary [25, 30]. Bronchoscopic investigation should be
performed, although this has limited accuracy in identifying the
source of bleeding. Rigid bronchoscopy is considered most
suitable for massive PH, but a ﬂexible instrument is often
preferred because it is more convenient and can be used in
therapeutic irrigation [30, 50]. A chest CT scan is needed to
identify the bleeding site [30]. Conventional endobronchial
therapy (irrigation with cold saline or epinephrine solution,
according to local guidelines and drug approval status) may
have a role, but is thought to have limited effectiveness [25, 50].
Various other bronchoscopic therapies are considered useful,
including laser coagulation, electrocautery and argon plasma
coagulation [25]. For example, endobronchial argon plasma
coagulation was rapidly effective in a study of 56 patients with
PH due to lung neoplasms, although the stage of cancer was not
stated [51]. Patients with lung cancer were included in another
case series in which bronchoscopy-guided haemostatic
tamponade was effective in controlling life-threatening PH, but
the stage of cancer and the efﬁcacy of therapy in cancer patients
was not reported [52].
Bronchial arterial embolisation (BAE) has an important role
as ﬁrst-line therapy for PH, for persistent PH and in
preoperative stabilisation [30]. However, data in lung cancer
patients are limited [25] and in some cases suggestive of
a greater likelihood of recurrence compared with non-cancer
patients [53–55]. In one small recent series, BAE provided
symptom palliation with an immediate decrease or resolution
of bleeding in 24 out of 27 patients (89%). However, survival
was signiﬁcantly lower in patients with tumour-related PH than
in those with non-tumour-related bleeding (P = 0.004) [55].
The use of external beam radiation therapy has been
recommended for use in the management of non-massive PH
caused by unresectable lung cancer [25]. Radiotherapy has been
reported to resolve PH in ‡70% of treated patients [56, 57]. The
optimal radiotherapy regimen has not been established, although
evidence suggests that lower doses or shorter courses (two to ﬁve
fractions) may be as effective as higher doses or longer courses
[56, 57]. Results were recently reported from a large cohort of
1250 patients with NSCLC treated with short-course split-dose
palliative radiotherapy, of whom 250 had moderate or severe PH
(deﬁnition not provided). Treatment was reported to improve or
alleviate PH in 68% of patients [58]. Surgery may be considered
when BAE is unavailable or ineffective/likely to be ineffective [59]
and appears most effective when preceded by non-surgical
methods of bleeding control [60]. However, patients with
massive PH due to advanced lung cancer are generally not
candidates for surgery [25].
discussion and conclusions
Bevacizumab is an important treatment option that extends
survival in patients with advanced non-squamous NSCLC. Severe
PH is a rare but serious potential adverse effect that may occur
during treatment with bevacizumab and other anti-VEGF agents,
and which can also be a sequela of NSCLC itself. The criteria by
which patients are selected for suitability for bevacizumab have
evolved since PH was ﬁrst observed during its use. In particular,
patients with predominantly squamous histology and those with
a history of clinically signiﬁcant PH have been excluded from
therapy. These changes have been associated with a reduction in
the incidence of severe PH to <1% in the most recent studies of
bevacizumab in patients with NSCLC [12, 14].
An individualised risk–beneﬁt assessment should be
undertaken in all patients with NSCLC in whom bevacizumab
is being considered. However, this assessment is hampered by
the lack of robust predictive factors for severe PH. Historical
assumptions regarding risk factors for severe PH based on
limited phase II data (e.g. central tumour location) have not
been conﬁrmed by more recent research involving larger
numbers of patients. An important obstacle to further
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standardised and well-accepted radiological deﬁnitions of
tumour centrality the contact between tumour and mediastinal
structures. It remains to be seen whether advances in CT
scanning can help better deﬁne tumour location and invasion.
Further retrospective analyses of PH cases could be useful to
explore whether PH is related to a composite of clinical and
radiological risk factors. A prospective international
observational registry of severe PH cases may also be useful,
although there are considerable challenges in establishing and
maintaining such a resource. Challenges in establishing the risk
factors for severe PH in NSCLC include the small number of
cases and the difﬁculty in collecting accurate and complete
information (e.g. due to rapid fatality, a lack of autopsy data
and the lack of a standardised data collection procedure). As
well as the need for clinical research, preclinical research (e.g.
using tumour xenograft models) is also required to elucidate
the pathophysiology of PH and its relationship with anti-VEGF
agents. Key aspects for such research include the importance of
squamous histology and the contributions of vessel
permeability, hypertension and vessel wall erosion.
In conclusion, while acknowledging the limitations in the
data, this group offers the following consensus conclusions
regarding bevacizumab therapy and PH:
 Patients with NSCLC are at an increased risk of PH owing to
the underlying disease process, although the
pathophysiological mechanisms are poorly understood and
robust data on the background incidence of clinically
signiﬁcant and severe PH are lacking.
 PH is a rare but serious potential adverse event during
treatment of non-squamous NSCLC with bevacizumab and
other anti-VEGF agents. The mechanisms by which anti-
VEGF agents induce PH are unclear and other factors/co-
morbidities are insufﬁcient to guide treatment selection.
 Patients with predominantly squamous histology and/or
history of grade ‡2 PH (deﬁned as bright red blood of ‡2.5 ml
within 3 months before randomisation) should not receive
bevacizumab, as these groups were excluded from pivotal
trials.
 No clinical or radiological features (including cavitation and
central tumour location) have been shown to be reliable
predictive factors for severe PH in bevacizumab-treated
patients. Major blood vessel inﬁltration and bronchial vessel
inﬁltration, encasement and abutting, may predict PH.
However, standardised radiological criteria for deﬁning
inﬁltration have not been established. Hypothetically, dilation
of the bronchial artery could be a risk factor for PH, but no
data exist to support this.
 Eligibility for bevacizumab is not affected by patient age,
performance status, anticoagulant or antiplatelet therapy.
 Oncologists, pulmonologists and radiologists should
collaborate closely in the evaluation and management of
patients with NSCLC.
 The risk : beneﬁt ratio for bevacizumab therapy should be
discussed with the patient.
 A high-resolution CT scan should be used to assess PH
occurring in non-squamous NSCLC patients treated with
bevacizumab.
 The optimal management of clinically signiﬁcant PH in
patients with advanced non-squamous NSCLC has not been
established. Bronchoscopic therapies (e.g. laser coagulation,
electrocautery and argon plasma coagulation) and BAE may
be useful. Radiotherapy and surgery may have a role in
salvage therapy on an individualised basis.
 Key areas for future research include the pathophysiology of
PH and its relationship with anti-VEGF agents and the
clinical risk factors for PH in patients with NSCLC.
It is hoped that this guidance—based on available
evidence—helps practising clinicians to undertake an
individualised risk–beneﬁt assessment with regard to PH in
patients with advanced non-squamous NSCLC in whom
bevacizumab therapy is being considered.
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